Acute Myeloid Leukemia — Trials

Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 789
Recruiting: 466
Ph III recruiting: 45
Growth YoY: +5%
Industry share: 19%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 38.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (534)

clinicaltrialsPublishedShowing 51–100 of 377 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07153497	Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)	not yet recruiting	Phase 2	132	National Cancer Institute (NCI)NIH	0	Sep 9, 2026	clinicaltrials
NCT03383575	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome	recruiting	Phase 2	63	M.D. Anderson Cancer CenterOTHER	1	Sep 4, 2026